About OASIS 4 OASIS 4 was a 64-week phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 ) with one or more weight-related comorbidities
BPC-157 offers a unique advantage: it may promote healing while allowing continued training with less pain and inflammation
Increasing use in sports nutrition and weight management supplements is fueling market growth
It specifically targets medications FDA-approved for weight loss, while leaving standard diabetes medications under regular Part D rules
Ali, Beverly Hills Concierge Doctor Who Should Consider BPC-157
At Total Anti-Aging and Wellness , we offer medically supervised weight loss solutions designed to help you safely lose weight , improve your health, and finally reach your weight loss goals without relying on fad diets or frozen meal kits